NCT06074614|Recruiting
Neural Control of Breathing in Parkinson's Disease
NEURON-PD
Loading search results
NEURON-PD
Sponsor study identifier
observational
30
1 country
1
Study Start
October 30, 2023
Actual (reported)Primary Completion
May 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
May 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Breathing is a complex process, which can be controlled through voluntary command or neural control. Parkinson's disease (PD) is a progressive neurological disorder. Many individuals with PD experience respiratory problems, such as coughing difficulties or shortness of breath. Changes in neural control of breathing could be part of the reason of these respiratory problems. This study will measure whether neural control of breathing is impaired in individuals with PD compared to healthy individuals.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 3, 2023
Actual (reported)October 10, 2023
Actual (reported)October 30, 2023
Actual (reported)May 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
May 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Hypercapnic ventilatory response curve
Sensitivity slope of the ventilation increase per unit increase in PetCO2, as measured with a rebreathing technique.
baseline - during the test
Respiratory related evoked potential
A measure of cerebral cortical activity elicited by a short inspiratory occlusion, expressed in the presence, latency and amplitude of components Nf, P1, N1, P2 and P3.
baseline - during the test
Transcranial magnetic stimulation
Interstimulus interval curves, using a conditioning stimulus at 80% and a test stimulus at 125%.
baseline - during the test
FVC
baseline - during the test
FEV1
baseline - during the test
MIP
baseline - during the test
MEP
baseline - during the test
Participants with clinically confirmed Parkinson's disease, Hoehn and Yahr stage 1 to 3.
Participants without Parkinson's disease.
Control of breathing is predominantly regulated by feedback of the central chemoreceptors. All chemoreceptors are sensitive to changes in partial pressure of carbon dioxide and via acid-base reactions to hydrogen concentration. The hypercapnic ventilatory response test shows the relationship between end-tidal PCO2 and the resulting minute ventilation.
Healthy participants: volunteers. Age- and sex-matched to the participants with Parkinson's disease. Participants with Parkinson's disease: recruited through the outpatient registry at the Radboud University Medical Center that have approved contact for research purposes.
Radboudumc
Nijmegen, Gelderland, 6500 HB, Netherlands
Jonne Doorduin, PhD
Radboud University Medical Center
First Submitted
October 3, 2023
First Posted
October 10, 2023
Study Start
October 30, 2023
Actual (reported)Primary Completion
May 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
TMS-related Measures as Biomarker of Cognitive Impairment in PD
Real-PD Trial: Development of Clinical Prognostic Models for Parkinson's Disease
The RREP is a measure of cerebral cortical activity elicited by short inspiratory occlusion or breathing against inspiratory resistive loads and quantifies the initial arrival and further processing of sensory afferent respiratory information in the cortex.
Transcranial magnetic stimulation of the diaphragm is an established tool for investigating the cortical excitability related to breathing. TMS will be delivered over the vertex using a magnetic stimulator and a 110mm double cone coil.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Study Completion
May 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 20, 2024
Record last verified: 2024-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: